The major side effect of olanzapine is significant weight gain, which often triggers a cascade of related metabolic problems including elevated blood sugar, increased blood fats, and a higher risk of developing type 2 diabetes. Among all atypical antipsychotic medications, olanzapine and clozapine carry the greatest risk for weight gain, and this side effect is so common that roughly 80% of patients experience a clinically meaningful increase in body weight within the first year of treatment.
How Much Weight Gain to Expect
The numbers vary depending on how long someone takes olanzapine, but they’re consistently substantial. In a meta-analysis of short-term trials, patients gained an average of about 4 kg (roughly 9 pounds) over just 10 weeks. Over 12 weeks in first-episode patients, the average gain was 7.9 kg (about 17 pounds), with over 80% of patients gaining more than 7% of their starting body weight. That threshold matters because clinicians consider a 7% increase the point where health risks begin climbing.
Longer treatment leads to more weight. Patients on olanzapine for a year at a typical dose gained an average of about 12 kg (26 pounds) in one study, and a similar result of 11 kg (24 pounds) showed up in another group treated for roughly seven months. Most of the gain happens in the first 9 to 10 months, after which it tends to plateau for many people.
Teenagers are especially vulnerable. They tend to gain more weight than adults and are also more likely to develop elevated blood fats and liver problems while taking olanzapine.
Why Olanzapine Causes More Weight Gain Than Other Antipsychotics
Not all antipsychotic medications carry the same metabolic risk. Olanzapine sits at the top of the scale alongside clozapine, while medications like aripiprazole and ziprasidone cause minimal weight change. Risperidone and quetiapine fall somewhere in the middle. For context, quetiapine users gained about 2 to 3 kg over a year in clinical trials, while aripiprazole users gained less than 1 kg over four weeks, essentially no different from a placebo.
Olanzapine drives weight gain largely by increasing appetite. It interacts with histamine receptors in the brain that regulate hunger signaling, essentially turning up the drive to eat. This isn’t a matter of willpower. The medication changes the brain’s appetite-control system in a way that makes people genuinely hungrier, and the increased calorie intake leads to fat accumulation.
Blood Sugar, Cholesterol, and Diabetes Risk
Weight gain is the most visible problem, but what happens beneath the surface can be more dangerous. Olanzapine can raise blood sugar levels, sometimes significantly. Some patients develop full hyperglycemia, experiencing extreme thirst, frequent urination, intense hunger, blurred vision, and fatigue. In rare cases, this can progress to a serious condition called diabetic ketoacidosis, which causes nausea, vomiting, shortness of breath, and fruity-smelling breath.
Blood fat levels also tend to rise. Olanzapine can increase triglycerides and cholesterol, which over time raises cardiovascular risk. These changes can happen even in people who don’t gain a dramatic amount of weight, though the two problems usually go hand in hand.
Because of these risks, current guidelines call for metabolic monitoring on a set schedule: blood sugar and a lipid panel at baseline before starting the medication, a lipid check at 4 weeks (specifically for olanzapine, quetiapine, and clozapine), both blood sugar and lipids again at 12 weeks, and then blood sugar annually going forward. If you’re taking olanzapine and haven’t had these tests done, it’s worth asking about them.
Other Side Effects Worth Knowing
While metabolic changes are the headline concern, olanzapine has a broader side effect profile. Common effects that many people experience include drowsiness, dry mouth, constipation, dizziness when standing up quickly, and restlessness. Joint and muscle pain in the arms, legs, or back is also frequently reported. Some people notice hormonal effects like breast enlargement, breast discharge, or changes in menstrual cycles.
Olanzapine can also impair your body’s ability to regulate temperature, making overheating more likely during hot weather or intense physical activity. This is easy to overlook but important to be aware of during summer months or exercise.
The risk of movement disorders, the involuntary muscle twitches and repetitive motions known as tardive dyskinesia, is lower with olanzapine than with older antipsychotic medications. Studies have found that olanzapine carries a significantly lower risk of these problems compared to older drugs like haloperidol. Still, the risk isn’t zero, and uncontrollable movements of the face or body should be reported promptly.
Risks for Older Adults
Olanzapine carries a boxed warning, the most serious type of safety alert, for elderly patients with dementia-related psychosis. Across 17 placebo-controlled trials of atypical antipsychotics in this population, the death rate was about 4.5% in treated patients compared to 2.6% in those receiving a placebo, representing roughly 1.6 to 1.7 times the risk. Deaths were most often cardiovascular (heart failure, sudden death) or related to infections like pneumonia. Older adults with dementia also face an elevated risk of stroke.
What Happens When You Stop Taking It
Discontinuing olanzapine can produce its own set of challenges. In a large survey of people who attempted to stop antipsychotic medications, 72% reported classical withdrawal effects including nausea, tremors, anxiety, agitation, and headaches. More than half of those people rated the withdrawal as severe. Insomnia and intense nervousness were the most commonly reported symptoms in open-ended responses, and about 18% experienced psychosis during the withdrawal period.
Stopping isn’t quick for many people. Nearly a quarter of respondents took at least a year to fully withdraw, and 26% had tried four or more times before succeeding. Gradual tapering rather than abrupt discontinuation is the standard approach, and the process generally requires close coordination with a prescriber who can adjust the pace based on how you’re responding.
Comparing Olanzapine to Alternatives
If you’re weighing olanzapine against other options, the metabolic trade-off is the key distinction. Olanzapine is an effective antipsychotic, but the weight and metabolic burden is meaningfully higher than most alternatives. In one switching study, patients who moved from conventional antipsychotics to olanzapine gained about 2.2 kg over four months, while those switched to risperidone had no weight change at all. Patients who switched from olanzapine to quetiapine in another study experienced weight loss, suggesting the effect is at least partially reversible.
The hierarchy is fairly well established: clozapine and olanzapine carry the highest metabolic risk, risperidone and quetiapine sit in the middle, and ziprasidone and aripiprazole have the lowest impact on weight. That said, effectiveness varies from person to person, and for some patients olanzapine works where other medications haven’t. The decision often comes down to balancing symptom control against metabolic side effects, with regular monitoring to catch problems early.